CLOSE

Giuseppe Curigliano

highlight

  • Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.

Curigliano G, Pivot X, Cortés J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A.

Breast. 2013 Oct;22(5):650-6. doi: 10.1016/j.breast.2013.07.037. Epub 2013 Aug 17

  • CLINICAL ACTIVITIES

    Dr. Giuseppe Curigliano is Director of the Division of New Drugs Development for Innovative Therapies at the European Institute of Oncology and is responsible for the Department of Medical Hospitalization for solid tumors. His staff includes four doctors, two of them structured, and two freelance consultants. The Division activities take place in the Departments of Hospitalization, Day Hospital and Clinic and are complemented by the activity of two research nurses and two data managers. He is a member of the Advisory Board of the clinical and research program on Breast Cancer and the program on Urogenital Cancer. In 2013, the Division completed 1393 outpatient services and 1500 Day Hospital activities in the context of clinical trials with innovative treatments and experimental therapies (mainly in breast cancer). The Division has provided 600 services for patients admitted in the medical area.

     

    Dr. Curigliano is responsible for the therapeutic planning of patients with metastatic solid tumors, present at IEO every week to evaluate their inclusion on clinical trials with innovative treatments in phase 0, I and II studies for all solid tumors.

  • RESEARCH ACTIVITIES
  • EDUCATIONAL ACTIVITIES

PARTNERSHIP

Università degli Studi di Milano Ecancer Medical Science IFOM-IEO Campus

CREDITS

Ministero della Salute Joint Commission International Breastcertification bollinirosa

© 2013 Istituto Europeo di Oncologia - via Ripamonti 435 Milano - P.I. 08691440153 - Codice intermediario fatturazione elettronica: A4707H7

IRCCS - ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO